A $72M ARR healthcare SaaS acquisition — analyzed by 6 AI agents across 500 Monte Carlo paths. BUY at 78% confidence.
This case study contains simulated deal data for evaluation purposes. Please provide your details and acknowledge the confidentiality terms to access the full analysis.
Scroll down to explore the full MedFlow Analytics simulation.
Download Full Report (PDF)Or scroll down to read online
The Target
Healthcare SaaS — Clinical Analytics & Population Health
Annual Recurring Revenue
$72M
42% YoY growth
Net Revenue Retention
156%
Best-in-class expansion
Enterprise Clients
340+
Hospital systems & health networks
MedFlow Analytics provides clinical analytics and population health management software to hospital systems across the United States. The platform integrates with major EHR systems (Epic, Cerner, MEDITECH) to deliver real-time operational intelligence, predictive risk models, and regulatory compliance dashboards.
Output from 6 agents across 500 Monte Carlo scenario paths.
Verdict
BUY at 78% confidence
Recommended Entry
$151M – $180M
10.5x – 14.5x EV/EBITDA
62%
Probability of 3x+ MOIC
4.2%
Probability of capital loss
4.1x
Mean MOIC
~31%
Median IRR
Probability-weighted exit scenarios across revenue growth, margin expansion, multiple compression, and competitive dynamics.
| Scenario | Exit EV | MOIC | IRR | Description |
|---|---|---|---|---|
| P5 Stress | $98M | 0.5x | NM | Full EHR encroachment + regulatory setback + churn cascade |
| P10 | $198M | 1.1x | ~2% | EHR encroachment + churn + margin miss |
| P25 | $456M | 2.5x | ~20% | Moderate growth, limited margin expansion |
| P50 Median | $698M | 3.9x | ~31% | Base: 28% growth, 26% margin, 12.5x exit |
| P75 | $943M | 5.2x | ~39% | Strong growth + margin expansion + tuck-ins |
| P90 | $1,247M | 6.9x | ~47% | Accelerated growth, 30%+ margins |
| P95 Bull | $312M* | 8.4x | ~53% | Market leadership + roll-up + IPO exit |
* P95 Exit EV: $1,518M. "$312M" refers to the P95 bull-case equity value at entry.
Return Distribution
Distribution skewed right. 62% of paths deliver 3x+ MOIC. Median 3.9x. Mean 4.1x. Capital loss probability 4.2%.
Three risk cascades the simulation surfaced that traditional CDD would likely miss.
If Epic restricts API access and launches bundled analytics at 50% lower cost, MedFlow's core moat — EHR integration depth — erodes from a differentiator to a dependency. Customer switching costs drop. Renewal rates compress.
Impact on MOIC
0.4–0.6x
Trigger Signal
Epic Cosmos roadmap announcements, API deprecation notices
Mitigation
Multi-EHR diversification, proprietary data layer, API-agnostic architecture
Professional services stuck at 18% of revenue signals a product gap — hospitals need customization the platform can't deliver out of the box. EBITDA stalls at 21–22% vs. 25%+ plan. The growth looks great, but the margin trajectory tells a different story.
Impact on MOIC
2.4x median
Trigger Signal
PS revenue growing faster than license, implementation backlogs
Mitigation
Product investment in self-serve config, partner ecosystem for services
Health Catalyst acquires an NLP competitor, Innovaccer undercuts on price, and tuck-in acquisition targets get snapped up by competitors. MedFlow gets squeezed from above and below simultaneously. Buy-and-build thesis collapses.
Impact on MOIC
1.0–1.5x at $180M
Value destruction at $209M
Trigger Signal
M&A announcements in health analytics, Innovaccer pricing moves
Mitigation
Pre-sign LOIs with tuck-in targets, accelerate product differentiation
Entry price sensitivity — where the margin of safety lives.
Conservative Entry
$151M
4.6x median MOIC
Maximum margin of safety
Recommended Range
$151M – $180M
3.9x median MOIC
Best risk/return balance
Aggressive Entry
$209M
3.3x median MOIC
Pincer risk = value destruction
The pricing insight alone is worth the engagement fee. Every $10M in entry price moves the median MOIC by ~0.2x. At $151M, you have a 68% probability of 3x+ returns and a meaningful buffer against the competitive pincer. At $209M, the pincer scenario means value destruction. The simulation doesn't just say "buy" — it shows where the margin of safety lives.
32-page IC-ready report generated in under 48 hours.
Monte Carlo distributions with P5–P95 exit scenarios
Sensitivity tornado plots across 12 key variables
Customer segmentation by churn risk and expansion potential
Competitive moat durability scoring with interaction effects
Regulatory timeline and compliance gap analysis
Three deal-killer cascades with probability-weighted outcomes
100-day value creation roadmap with quick wins
Full provenance — every conclusion traces to source data
The complete MedFlow Analytics simulation report with all charts, tables, and source annotations.
Download Full Report (PDF)Six agents. 500 scenarios. 48 hours. The MedFlow simulation is a sample — imagine this depth of analysis on the deal sitting on your desk right now.